IL17A and psoriasis: To analyze the impact of psoriasis on the retention of IL-17 inhibitors, we conducted a subgroup analysis by dividing the IL-17 inhibitor group into patients who used IL-17 inhibitors for psoriasis aggravation (n = 13) and patients who used IL-17 inhibitors for other reasons (n = 61).